Krzysztof Selmaj, MD, PhD

Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.

Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.

Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.

Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.

Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.

Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.

Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.

Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.

Krzysztof Selmaj, MD, PhD, wraps up this series highlighting strategies for educating patients with relapsing-remitting multiple sclerosis (RRMS) about sphinogine-1-phospate (S1P) receptor modulators.

Krzysztof Selmaj, MD, PhD, presents the key results on the safety of other sphinogine-1-phospate (S1P) receptor modulators, such as fingolimod and ponesimod, in the treatment of multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, presents the results of a pooled safety study of ozanimod as treatment for relapsing-remitting multiple sclerosis (RRMS).

Krzysztof Selmaj, MD, PhD, provides key clinical considerations when switching patients with multiple sclerosis (MS) to sphinogine-1-phospate (S1P) receptor modulator treatment.

Krzysztof Selmaj, MD, PhD, provides his clinical expertise on strategies to monitor patients with relapsing-remitting multiple sclerosis (RRMS) taking sphinogine-1-phospate (S1P) receptor modulators.

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, explains the tissue selectivity of sphinogine-1-phospate (S1P) receptor modulators and the clinical considerations that arise when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, discusses the treatment landscape for relapsing-remitting multiple sclerosis (RRMS) and where sphinogine-1-phospate (S1P) receptor modulators fit in.